Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for NONOF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for NONOF and 80,000+ other tickers.
See exactly how NONOF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NONOF and 80,000+ other tickers.
Novo Nordisk A/S operates as a prominent global pharmaceutical firm, dedicated to the discovery, development, production, and distribution of a wide array of medicinal products. Its extensive operations are primarily structured into two distinct divisions: Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment offers comprehensive solutions, encompassing various insulin preparations, GLP-1 receptor agonists along with their delivery systems, oral antidiabetic medications, treatments for weight management, and therapies addressing other chronic health…
No recent news available.